SeaSpine Holdings Corporation (SPNE)
(Delayed Data from NSDQ)
$15.36 USD
+0.73 (4.99%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.40 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$15.36 USD
+0.73 (4.99%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.40 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
SeaSpine Holdings (SPNE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of -40% and 0.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Avanos Medical (AVNS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SeaSpine Holdings (SPNE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
SeaSpine (SPNE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SeaSpine Holdings (SPNE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of -8.57% and 3.64%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SARTORIUS (SARTF) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
SARTORIUS (SARTF) delivered earnings and revenue surprises of 6.56% and 6.09%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SeaSpine Holdings (SPNE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of -28.57% and 3.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Will SeaSpine Holdings (SPNE) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
SeaSpine (SPNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SeaSpine (SPNE) Moves 5.8% Higher: Will This Strength Last?
by Zacks Equity Research
SeaSpine (SPNE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
SeaSpine Holdings (SPNE) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of -44.44% and 1.33%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -29.03% and 0.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Tandem Diabetes Care, Inc. (TNDM) Q4 Earnings Lag Estimates
by Zacks Equity Research
Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -20% and 6.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Artivion (AORT) Reports Break-Even Earnings for Q4
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 100% and 1.79%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
SeaSpine (SPNE) Enhances ACDF Procedure With Admiral ACP System
by Zacks Equity Research
SeaSpine's (SPNE) next-generation Admiral ACP System covers the largest segment in the estimated $1.30-billion cervical spine surgery market.
SeaSpine Holdings (SPNE) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of -54.84% and -3.46%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
5 Stocks to Deflect Delta Variant Curveball From Orthopedic Space
by Debanjana Dey
OrthoPediatrics (KIDS), Orthofix (OFIX), Zimmer Biomet (ZBH), Stryker (SYK) and SeaSpine (SPNE) are expected to hold ground despite a challenging business climate.
SeaSpine Holdings (SPNE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of 2.86% and 2.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will SeaSpine Holdings (SPNE) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
SeaSpine (SPNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orthopedic Space Gains Momentum in 2021: 5 Stocks in Focus
by Debanjana Dey
Here are five orthopedic device stocks, Integra (IART), Conformis (CFMS), SeaSpine (SPNE), Zimmer Biomet (ZBH), Orthofix (OFIX), which are expected to continue their run over the next few months.
SeaSpine (SPNE) Surges 13.2%: Is This an Indication of Further Gains?
by Zacks Equity Research
SeaSpine (SPNE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
SeaSpine Holdings (SPNE) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of -42.31% and -2.16%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Will SeaSpine Holdings (SPNE) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
SeaSpine (SPNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SeaSpine Holdings (SPNE) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
SeaSpine (SPNE) delivered earnings and revenue surprises of 20.00% and 0.25%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for GrowGeneration's (GRWG) Q3 Earnings?
by Zacks Equity Research
GrowGeneration's (GRWG) third-quarter results are likely to reflect ongoing momentum in retail and online sales.
Aurora Cannabis (ACB) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) fiscal first-quarter results are likely to reflect solid prospects in the Canadian market.
Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet's (ZBH) Dental product volumes are expected to have declined significantly in the third quarter due to the extremely elective nature of the products.